Literature DB >> 1533934

A vaccine carrier derived from Neisseria meningitidis with mitogenic activity for lymphocytes.

M A Liu1, A Friedman, A I Oliff, J Tai, D Martinez, R R Deck, J T Shieh, T D Jenkins, J J Donnelly, L A Hawe.   

Abstract

Protein carriers vary in their ability to increase the immunogenicity of poorly immunogenic or T-lymphocyte-independent antigens. We examined one such carrier, the outer membrane protein complex derived from Neisseria meningitidis serogroup B strain B11, in an attempt to determine why this outer membrane protein complex was more immunogenic in young infants and in relevant animal models than two other carriers used in conjugates made with Haemophilus influenzae type b polysaccharide, a T-cell-independent antigen. A single protein of the outer membrane protein complex, the class 2 porin protein, was purified and shown to function as a T-helper lymphocyte carrier protein. Unexpectedly, it was also found to have mitogenic activity for lymphocytes that was not due to lipopolysaccharide. This mitogenic activity appears to date to be unique to this carrier protein of the carrier proteins tested and may contribute to the ability of the H. influenzae type b conjugate vaccine made with the outer membrane protein complex to generate IgG anti-polysaccharide antibody responses in mice and infant monkeys and protective immune responses in infants less than 6 months of age.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1533934      PMCID: PMC49137          DOI: 10.1073/pnas.89.10.4633

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

Review 1.  The role of bacterial polysaccharide capsules as virulence factors.

Authors:  E R Moxon; J S Kroll
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

2.  Safety and immunologic response to Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in 1- to 6-month-old infants.

Authors:  D V Madore; C L Johnson; D C Phipps; L A Popejoy; R Eby; D H Smith
Journal:  Pediatrics       Date:  1990-03       Impact factor: 7.124

3.  Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB): clinical evaluation.

Authors:  V I Ahonkhai; L J Lukacs; L C Jonas; H Matthews; P P Vella; R W Ellis; J M Staub; K T Dolan; C M Rusk; G B Calandra
Journal:  Pediatrics       Date:  1990-04       Impact factor: 7.124

Review 4.  Polysaccharide-protein conjugate vaccines for the prevention of Haemophilus influenzae type b disease.

Authors:  G A Weinberg; D M Granoff
Journal:  J Pediatr       Date:  1988-10       Impact factor: 4.406

5.  Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen unterminally coupled to the diphtheria protein CRM197.

Authors:  P W Anderson; M E Pichichero; E C Stein; S Porcelli; R F Betts; D M Connuck; D Korones; R A Insel; J M Zahradnik; R Eby
Journal:  J Immunol       Date:  1989-04-01       Impact factor: 5.422

6.  Immunogenicity of Haemophilus influenzae type b conjugate vaccines in infant rhesus monkeys.

Authors:  P P Vella; R W Ellis
Journal:  Pediatr Res       Date:  1991-01       Impact factor: 3.756

Review 7.  Clinical experience with Haemophilus influenzae type b conjugate vaccines.

Authors:  P H Mäkelä; J Eskola; H Peltola; A K Takala; H Käyhty
Journal:  Pediatrics       Date:  1990-04       Impact factor: 7.124

8.  CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : II. IMMUNOLOGICAL SPECIFICITY OF SYNTHETIC SUGAR-PROTEIN ANTIGENS.

Authors:  O T Avery; W F Goebel
Journal:  J Exp Med       Date:  1929-09-30       Impact factor: 14.307

9.  Antibody response of patients with Hodgkin's disease to protein and polysaccharide antigens.

Authors:  G R Siber; S A Weitzman; A C Aisenberg
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

10.  Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.

Authors:  R Schneerson; O Barrera; A Sutton; J B Robbins
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

View more
  10 in total

1.  Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.

Authors:  Nina Ekström; Heidi Ahman; Jouko Verho; Jukka Jokinen; Merja Väkeväinen; Terhi Kilpi; Helena Käyhty
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

2.  Trypanosoma cruzi mitochondrial malate dehydrogenase triggers polyclonal B-cell activation.

Authors:  C L Montes; E I Zuñiga; J Vazquez; C Arce; A Gruppi
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

3.  Variable region expression in the antibody responses of infants vaccinated with Haemophilus influenzae type b polysaccharide-protein conjugates. Description of a new lambda light chain-associated idiotype and the relation between idiotype expression, avidity, and vaccine formulation. The Collaborative Vaccine Study Group.

Authors:  D M Granoff; P G Shackelford; S J Holmes; A H Lucas
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

Review 4.  Content and dynamics of the human antibody variable region repertoire to the Haemophilus influenzae type b polysaccharide.

Authors:  D C Reason; A H Lucas
Journal:  Springer Semin Immunopathol       Date:  1993

5.  Outer membrane proteins as a carrier for detoxified lipooligosaccharide conjugate vaccines for nontypeable Haemophilus influenzae.

Authors:  T H Wu; X X Gu
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

6.  Dynamics of the murine humoral immune response to Neisseria meningitis group B capsular polysaccharide.

Authors:  J Colino; I Outschoorn
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

7.  Modulation of the biological activities of meningococcal endotoxins by association with outer membrane proteins is not inevitably linked to toxicity.

Authors:  E K Quakyi; H D Hochstein; C M Tsai
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

8.  Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models.

Authors:  L L Van De Verg; A B Hartman; A K Bhattacharjee; B D Tall; L Yuan; K Sasala; T L Hadfield; W D Zollinger; D L Hoover; R L Warren
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

9.  The V-region repertoire of Haemophilus influenzae type b polysaccharide antibodies induced by immunization of infants.

Authors:  G H Chung; K H Kim; R S Daum; R A Insel; G R Siber; S Sood; R K Gupta; C Marchant; M H Nahm
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

10.  Gonococcal invasion of epithelial cells driven by P.IA, a bacterial ion channel with GTP binding properties.

Authors:  J P van Putten; T D Duensing; J Carlson
Journal:  J Exp Med       Date:  1998-09-07       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.